Denali Therapeutics Inc (NASDAQ: DNLI) on Friday, plunged -10.12% from the previous trading day, before settling in for the closing price of $21.25. Within the past 52 weeks, DNLI’s price has moved between $14.56 and $33.33.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 350.08% annually for the last half of the decade. The company achieved an average annual earnings per share of -162.05%. With a float of $124.59 million, this company’s outstanding shares have now reached $143.84 million.
In an organization with 445 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 102.06%, operating margin of 165.42%, and the pretax margin is 140.13%.
Denali Therapeutics Inc (DNLI) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Denali Therapeutics Inc is 13.48%, while institutional ownership is 88.51%. The most recent insider transaction that took place on Jan 06 ’25, was worth 247,796. In this transaction Chief Medical Officer of this company sold 12,255 shares at a rate of $20.22, taking the stock ownership to the 178,580 shares. Before that another transaction happened on Jan 07 ’25, when Company’s Chief Medical Officer sold 2,907 for $20.81, making the entire transaction worth $60,495. This insider now owns 175,673 shares in total.
Denali Therapeutics Inc (DNLI) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -162.05% per share during the next fiscal year.
Denali Therapeutics Inc (NASDAQ: DNLI) Trading Performance Indicators
Denali Therapeutics Inc (DNLI) is currently performing well based on its current performance indicators. A quick ratio of 9.98 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.76, a number that is poised to hit -0.82 in the next quarter and is forecasted to reach -2.97 in one year’s time.
Technical Analysis of Denali Therapeutics Inc (DNLI)
Let’s dig in a bit further. During the last 5-days, its volume was 1.29 million. That was better than the volume of 1.2 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 58.89%. Additionally, its Average True Range was 1.27.
During the past 100 days, Denali Therapeutics Inc’s (DNLI) raw stochastic average was set at 2.93%, which indicates a significant decrease from 12.15% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 64.98% in the past 14 days, which was higher than the 56.66% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $24.36, while its 200-day Moving Average is $23.09. However, in the short run, Denali Therapeutics Inc’s stock first resistance to watch stands at $20.38. Second resistance stands at $21.65. The third major resistance level sits at $22.51. If the price goes on to break the first support level at $18.25, it is likely to go to the next support level at $17.39. The third support level lies at $16.12 if the price breaches the second support level.
Denali Therapeutics Inc (NASDAQ: DNLI) Key Stats
Market capitalization of the company is 2.75 billion based on 143,922K outstanding shares. Right now, sales total 330,530 K and income totals -145,220 K. The company made 0 K in profit during its latest quarter, and -107,190 K in sales during its previous quarter.
